CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new ...
-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- CRISPR Therapeutics is advancing a pipeline of in ...
Crispr Therapeutics (($CRSP)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Long-term Follow-up ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...
(MENAFN- GlobeNewsWire - Nasdaq) -Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460, is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback